HP
GENB

Harbourvest Partners’s Generate Biomedicines GENB Stock Holding History

Harbourvest Partners’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.1M Hold
1,722,210
– – 17.09% 2
2026
Q1 		$21.5M Buy
+1,722,210
New +$21M 21.33% 2

Other funds holding GENB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Harbourvest Partners's GENB Position: Q2 2026 in Review

Harbourvest Partners held its Generate Biomedicines (GENB) position steady in Q2 2026 at 1,722,210 shares worth $29.1M. The position accounts for 17.09% of the portfolio, ranked #2.

Harbourvest Partners first reported a position in GENB in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Harbourvest Partners held 1,722,210 shares of Generate Biomedicines worth $29.1M as of Q2 2026.
  • Harbourvest Partners left its Generate Biomedicines share count unchanged in Q2 2026.
  • Generate Biomedicines made up 17.09% of Harbourvest Partners's portfolio in Q2 2026, its #2 holding.
  • Harbourvest Partners first reported a position in Generate Biomedicines in Q1 2026 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Harbourvest Partners's 13F filing for Q2 2026, filed 14 Aug 2026.